Gerresheimer AG has announced a change on its Supervisory Board, with Klaus Röhrig appointed to the role until the next Annual General Meeting in June 2026. The company said the update reflects its changed shareholder structure.
Supervisory Board Transition
Röhrig is co-founder and Co-Chief Investment Officer of Active Ownership Group.
He replaces Dr. Dorothea Wenzel, who made her position available to support a Supervisory Board composition that matches the company’s current shareholder base.
With this appointment, Röhrig also takes over Wenzel’s responsibilities on the Audit Committee.
Gerresheimer noted that Wenzel has contributed significantly to the committee’s work, particularly in fulfilling its oversight duties.
Chairman Dr. Axel Herberg thanked Wenzel for her service, highlighting her professional expertise and the value she brought during her time on the Supervisory Board and the Audit Committee.
Next Steps For The Board
Röhrig will stand for election at the next Annual General Meeting, scheduled for 3 June 2026.
At that meeting, four shareholder representatives in total will be up for election on the co-determined Supervisory Board.
Gerresheimer said these changes form part of its ongoing responsibility to align governance structures with shareholder interests and the company’s long-term direction.
About Gerresheimer
Gerresheimer is a global supplier of containment and drug-delivery solutions for the pharma, biotech and cosmetics sectors.
Its product range includes vials, cartridges, ampoules, syringes, pens, inhalers, auto-injectors, on-body devices, tablet containers, infusion bottles, dropper bottles and syrup bottles.
The group also develops digital solutions that support therapy and patient adherence.
Gerresheimer provides services across the value chain, including design, development, manufacturing and sustainability support, helping customers respond to growing demand for more efficient and environmentally aligned packaging.
The company operates more than 40 production sites in 16 countries across Europe, the Americas and Asia.
Together with Bormioli Pharma, Gerresheimer generated approximately €2.4 billion in revenue in 2024. The group employs around 13,600 people and is listed in the MDAX on the Frankfurt Stock Exchange.
Annual General Meeting Timeline
The company confirmed that the next Annual General Meeting will take place on 3 June 2026.
At this meeting, shareholders will vote on the proposed Supervisory Board candidates, including Röhrig, who is joining the board until that date.
Editor’s note: This article uses only information provided in Gerresheimer AG’s official announcement dated 20 November 2025.
